PROTECT-1: A prospective randomized trial of CCX282-B (Traficet-EN), a novel oral therapy targeting chemokine receptor 9 in Crohn's disease

Samankaltaisia teoksia

• Protect-1, a prospective randomized oral therapy evaluation of CCX282-B (Traficet-EN) in Crohn's disease trial
  Tekijä: Bekker, P, et al.
  Julkaistu: (2008)
• Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease
  Tekijä: Bekker, P, et al.
  Julkaistu: (2007)
• PROTECT-1 Maintenance Phase Study Results demonstrate efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Crohn's Disease
  Tekijä: Bekker, P, et al.
  Julkaistu: (2009)
• PROTECT-1 Study Demonstrated Efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Treatment of Patients with Moderate to Severe Crohn's Disease
  Tekijä: Keshav, S, et al.
  Julkaistu: (2009)
• A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease.
  Tekijä: Satish Keshav, et al.
  Julkaistu: (2013-01-01)